I'll kick off now. So welcome to the Q2 presentation. Since this is a virtual meeting, we have muted everybody's microphones, and we will unmute those at the end for the Q and A session. So today, it's myself, Geoff Verholte, CEO and Virgo Serbild, our CFO, who will walk you through the presentation today. Today actually marks a new era for us.
It's the first time we actually present as Alexeym Technologies. We rebranded the company from Biotech Pharmakon to Alexeym Technologies back in June. We are very proud of the new brand. It fits seamlessly and resonates well with our commitment to the Enzymes business being our core future
focus moving forward.
So with the new brand, we have a clear mission and vision. So our vision is with our daily work, we want to make an important contribution to a healthier world. Driven by this goal, our experienced scientists are constantly working to find and unlock new solutions. What this essentially means is that at the end of the day, for us, it's more than enzymes. We want to improve the health care down to the individual level of people like you and I.
Our mission, as experts in our field, we discover, develop and provide enzymes without compromises on a consistently high level to make our customers' lives easier by unlocking new solutions. And the key messaging here for us, it's really about enzymes without compromises. At the end of the day, why should our customers compromise their technologies? We provide really good enzymes with unique features, which allows them to develop the next generation technologies. So this is really what our enzymes are all about and where we're going in the future.
So the agenda for today is we're going to start with the highlights of Q2, and we're going to walk you through that. Then we'll talk about the updates for Alixar. We'll then walk you through the beta glucans. Birger will take you through the Q2 financials. Then I'll end by giving you an outlook to see so you can see what to expect for the remainder of the year.
And then we'll unmute to microphones and open up for Q and A session. Highlights. What we've seen is we've had in a nutshell, we've had a very good Q2, where we've seen strong underlying growth. On top of that, we've seen corona upsides contribute to the sales as well. So when you have a look at the main achievements, we can see that the group due to EBITDA was NOK 27,200,000 for the quarter.
That's versus minus NOK 500,000 for the same period last year. When you look at the Ardexyme sales for Q2, we had our best sales ever with £33,400,000 for Q2. Last year, we had so for the same period last year, it was CHF 9,000,000 This accounts for a 2 70% growth in the Arctic Diamonds business for Q2. When you look at the Arctic Diamonds sales, we do have some corona related upsides in the sale, and we have approximately €11,000,000 in Q2 related corona related sales. But it's important to stress, these are just upsides.
You take those upsides away, we still have very strong underlying growth in the main business. Also, we rebranded the company to IdeSymes Technologies, which I mentioned earlier. On the biotech feeder glucans front, we're seeing to be operating the business profitably. And in 2 consecutive quarters, we operate that business profitably. Could I kindly ask people to mute the microphones?
We have quite a bit of background noise there. So PRD Times update. We have I want to walk you through the commercial achievements. We as mentioned, we have we've grown the business 270% for ILEC9 in Q2. And there's 2 key contributing factors here.
Firstly, it's a therapeutic segment. This is the cell active nuclease portfolio where the SAN for short, these enzymes are sold into gene therapy and vaccine production, where they're used to make therapeutic viruses. And what we see is that the Therapeutic segment has contributed £34,000,000 to 25,000,000 sales. And this growth is largely driven by new customers coming on board as well as increasing orders of magnitude in excess of SEK 1,000,000 in Krona from our most well established customers. We have not seen any slowdown in the therapeutics segment with respect to corona.
We still see that it's still going feet ahead in the developments ongoing out there. Also during the quarter, we have seen new interest in the use of cyan enzymes for the development of COVID-nineteen vaccines. When you look at revenues though, there's not there is very little contribution of that to the revenues here at this stage. Since these projects are very new, people are developing COVID-nineteen vaccines. This is very new stuff.
Those projects are kicking off. So like the rest of our therapeutic customers, they will start buying sand in small quantities. And then as they progress through their developments, they will then put in increasingly more orders of larger sizes. Also a good example of where we're going here is we did sign a supply agreement with ReoTera. ReoTera is an Italian company who is a leader in developing DNA based vaccines.
They are going to use our SAN enzyme in the development of their COVID-nineteen vaccine. SAN will be used to streamline one critical step in the manufacturing process. And so basically, what like all therapeutic customers here we're working with, SAN is used to remove contaminating DNA from the virus, which is very important to avoid adverse effects. On the other driver for growth for Artezymes was COVID-nineteen upsides. And this relates to sales of multiple enzymes, but mainly the most sold enzyme here is the Cod UNG.
In terms of COVID-nineteen upside, that contributed 33% of total sales in RNAxymes. And I think mostly you've observed what's happened in the market when it comes to COVID-nineteen. Q2 is where the main peaks happened in most regions, and I think this is very much reflected in our sales as well. And I think what our operations team has done an excellent job here in Trump, so we've had that flexibility in order to take all orders that we received related to COVID-nineteen. So we're able to capture all commercial business related to that where there's been an interest in our enzyme.
But also, it's about preparing for the future. In COVID-nineteen, the upside is very nice, okay? But our interest here is really about capturing longer term potential. What we want to do is we want to make sure our enzymes are integrated into the next generation, the viral diagnostic tests for corona and other viruses as well. So with this, what we've done is we've already we rapidly scaled up the production batch sites for Quad UNG during the quarter.
So we're ready to have to serve future demand here. So we talked a bit about corona, but what I need to do is really stress. When we put corona sales to one side, there is strong underlying growth in the business. And our top line growth, if you take corona away, is very much progressing according to plan. When we look at corona upside, we just see this essentially icing on the cake.
I think all the business is progressing as planned. In terms of Arctic Times, we have been working on innovations, and Arctic Times has been recognized as a leading innovative company, which can make a contribution towards a fight against corona. And as part of a national initiative, Arctic's arms was awarded 2 grants from Innovation Norway towards developing technologies against corona. The first grant was for NOK 1,600,000 and that is towards accelerating the upscaling of sand production. We already had efforts ongoing here, but this just allows us to put more fuel on the fire.
We can put more resourcing behind it. We can also work with other national partners to fast track the scale up of these enzymes. And this rate fits timely with the foreseen commercial demand for both COVID virus and non COVID virus customer activities we're doing. So then the next grant we got was again for NOK 1,600,000. This grant relates the commercialization of enzymes supporting COVID-nineteen and viral diagnostic test development.
And as mentioned, our goal with COVID-nineteen, yes, we're enjoying the upside, but we more want to capture long term value by our enzymes being integrated into other companies' next generation COVID-nineteen and viad diagnostic tests. So with that, what we're going to do is we're going to build other enzymes around CODU NG, and these other enzymes will be very much optimized to work in viral diagnostics. So this way, what we can do, we can provide a much broader offering of enzymes to viral diagnostic test developers.
So we end
up giving a more complete offering to our customers and can take more of the value chain. A couple of examples such enzymes would be reverse transcriptases, thermostable polymerases, thermostable polymerases, our firm set polymerases are hot polymerases. However, polymerases we have on the market are cold polymerases. So by having the range of these different enzymes optimized for virologic diagnostics, we can serve the tests that are made in for PCR technologies and for non PCR technologies such as LAMP amplification technology. Okay.
We're going to change gears here and talk a little bit about biotech beta glucans. And in a nutshell, ViaTech Beta Glucans is operating profitably when you look at the business as a whole. For the 2 consecutive quarters, we've operated the biotech beta glucans profitably. In short, this is due to a combination of factors. 1, it relates to the structural reorganization we did back in December.
It also, we scaled back support for the Worgan business since we're divesting where we're divesting that business. We also see a nice sales growth in adjuvant sales. I'm going to walk you through each of these quickly. So first one in Animal Health. We saw lower Q2 sales compared to Q1 for the M Glucan product.
This was very much expected because we did get a large early order from our main customer in Q1, so we had some tailwinds there. With this business, we do expect fluctuation in sales for the remaining quarters. Overall, for the year, and as communicated earlier in previous presentations, we expect this business to be a flat business going forward. The Consumer Health business, we continue to see growth from the EMGuard sales. For the quarter, we had very strong growth compared to the quarter last year.
We grew it over 500% in Q2. Growth is driven by new customers. And also there are we do see upsides related to COVID-nineteen, where manufacturers are targeting immunodefense against coronavirus. So we approximately estimate 40% of the sales for Q2 here are related to coronavirus. When we look at the SVG sales relating to the adjuvant, we've had commitments to our customers committed to us demand for SPG for the neuroblastoma clinical trials they've been doing.
And linked to that annual commitment, we shipped the second order of SVG to them during the Q2. Also, we've been moving forward with a licensing deal we're doing with we're working on with a vaccine owner towards neuroblastoma. And here, a part of this process always when you have these meetings, it's important to have face to face meetings. And we managed to navigate around corona and had a face to face meeting at the end of the quarter in Trompster. And that was important because they needed to come and see the facilities for themselves and part of their due diligence.
So that helps drive the process forward. We had productive discussions and certainly that visit set the stage for the next stages here. When it comes to WALGAN, wound healing, sales were lower in Q2 compared to the same period last year. This was very much expected because we have made decisions to divest and we are looking at the core existing customers. Also during the quarter, we made a decision to discontinue all GaN production.
The decision was mainly due to the contract manufacturer we were using. That contract manufacturer has been aseptically filling the wall gown tube. The contract manufacturer filed for insolvency, which meant that they were unable to meet their commitments to produce the Worgen tubes. And there were some quality requirements they could not fulfill either. What we did was we did search around for alternative CMOs and we evaluated them.
But we found no feasible options materialized that we considered would be economically viable for us or would circumvent a very lengthy back order situation. So with that, we made a decision to discontinue the Wollam production. We have discontinuation. We are going to continue supplying Worgan stocks until they're depleted. We expect the Worganne stock to be depleted during the second half.
From a revenue perspective, we will see the Worgan sales phase out during the second half. However, when you look at the numbers, the numbers around WALCON have a very minor contribution to overall sales. So we don't see it having a major impact there in terms of our revenue contribution for the year. In terms of divestment process, does it have a negative impact? No, because at the end of the day, the whole process around divestment hasn't been about divesting the WALGAN, FORGAM II.
The process has actually been about divesting the technology platform, which is SVG for the development of a broader wound healing portfolio. And the beauty of that is that we have a hefty and substantial documentation package to back that up to a potential new owner. Regarding the divestment process, that is moving forward. However, it is moving forward at a bit of a slower place than originally planned. This is due to the corona situation.
I think when you look at the industry, it doesn't matter that this is for all processes right now, divestment processes. They are moving slower due to corona right now. Despite the slowdown, the discussions are ongoing with several interested parties. So that's a kind of a snapshot of where we are with the Biotech B, the Glucan's business. Now I'm going to hand over to Birger, who will walk you through the financials.
Thank you, Detro.
And I will give you a few more details on the underlying performance that Detro has talked about. And I think it's quite fair to say that we are proud of how we have managed to turn the group around from a loss making business into a profitable business. And this gives brings us straight into the kind of the core of the business where we talk about the Artixime sales. And if you look at the sales, Artixime had sales growth of more than 270% compared to the same quarter last year. We have managed to secure CHF 33,400,000 in sales revenues compared to CHF 9,000,000 at the same time last year and CHF 18,000,000 in Q1 this year.
And taking away the upsides related to the corona pandemic, we have still managed to have a substantial growth in the company by more than 150%, where we actually grown the company from €9,000,000 last year to €23,000,000 this year. And as Srecko said, the growth in the therapeutics segment has played a vital role in the sales now as they are continuing to grow and they had more than $11,000,000,000 in sales now for just for this quarter. And it's also important to remember that the therapeutic segment had 0 in sales in 2016. So we have seen a good growth in this part of the business. We also see that we have good growth in the therapeutic and in the research and diagnostics segment.
And we have an underlying growth of 130% compared to the same quarter last year. And this is also when we have taken away all of the upsides here. And by looking at the table on the right hand side here, you can see that the business has shown steady growth in basically all quarters over the last 2 years. But of course, there will always be quarters that can be lower than others. But overall, our ambition to have solid underlying growth in the business here.
And also, if you can see here, if you look at the sales figures from Q1 from Q1 2020 and Q4 2019, you can see that underlying growth was lower than Q4. But of course, when you take when you bring in the coronavirus upsides, you can see that we had a growth in this quarter as well. For the 1st 6 months, I think I'm just going to find some here. Yes. And looking at the 1st 6 months, we have an underlying growth of more than 120% for the business.
And including upsides, we have a growth of more than 200% compared to the 1st 6 months of 2019 here. Okay. I think we'll just move on to the performance to the financial performance. You can take the next slide, Latro. And as I already talked about in the previous slide, our sales have grown substantially both in the quarter and for the 1st 6 months.
And even though our sales have grown, we have only increased our expenses by SEK 1,000,000 on a quarterly basis and SEK 1,500,000 for the 1st 6 months. And of course, the increase in the operating expenses is explained by the restructuring we did in December last year and the refocusing we did. But also, of course, there have been some added expenses with increased activity levels we've had in the first half of the year. And of course, with increased sales and a small increase in operating expenses, we have achieved an EBITDA of close to CHF 25,000,000 for the quarter and close to CHF35 1,000,000 more than CHF35 1,000,000 for the 1st 6 months of the year. And also what is a little bit interesting and if you look at the table on the right hand side, you can see the relationship between sales and EBITDA here.
And from what we can see here is that when sales passes around €8,000,000 to €9,000,000 on a quarterly basis, basically everything drops down to the bottom line here. And this is also why we can show an EBITDA margin of 74% for the 1st 6 months and close to 68% for the 1st 6 months of the year. Yes. And I think moving on to the And looking at the non core part of the business now, Sales are close to $5,000,000 lower than we experienced in the Q1 this year. But compared to the same quarter last year, we have seen a growth of close to 3,000,000 euros Even though sales are lower, products mix has changed from a low margin business to the high margin business here.
Animal Health, that Jethro talked about, which is a low margin business for us, will continue to fluctuate from quarter to quarter, and we expect, as he said, annual sales to be flat here. But what is really positive now for the Q2 is that we have experienced good growth in the consumer health part of the business. And sales have now passed $5,000,000 for the quarter. And as Cecil talked about, $2,000,000 of these $1,000,000 can be allocated to the corona upsize related to the corona pandemic. But of course, we also see the increase in number of customers buying this product.
So there has been steady growth in our consumer health. And Wurgens sales, which we have decided to divest, had revenues of $800,000 for the quarter. And lower sales in this part of the business can, of course, be partly explained by the corona pandemic and a little bit setback in society, but also because there is uncertainty regards to future supply of Woolgen as we no longer have the CMO as they're supportive as well. And we don't expect any revenue. At the end of the year, we don't expect any more revenues from the Morgan part of the business unless we have a divestment the divestment is concluded.
And also for the 2nd straight quarter, we have managed to secure revenues from the adjuvant side of the business. And this one is actually on the same level as we experienced in the Q1. Looking at the performance side of the business here and as we continue to deliver positive results for the business. And this is the 2nd straight quarter that we have a positive EBITDA. And we have a positive EBITDA of more than SEK 4,000,000 in the quarter.
And of course, this is partly explained by the change in product mix, but it also is explained by that we have managed to reduce our expenses in this part of the business here. Also, you can see that from this from the table on the right side that we have managed now, we have good EBITDA margin as well. We had 27% in the Q1 and 38% in the Q2 and also giving us a close to 30% EBITDA margin for the 1st 6 months here as well. And as we have said now, we have decided to divest Volcan. And also by divesting Volcan, our expenses have been reduced significantly.
And also looking for the 1st 6 months, expenses are reduced by close to $5,000,000 for the 1st 6 months and a little bit more than $2,000,000 dollars for the Q2. And then going over to the group figures, Of course, given our performance for the 6 months that our performance for the 1st 6 months have been exceptional. We had an EBITDA for the Q2 of $27,000,000 compared to a loss of $500,000 in the same quarter last year. And also what we can see is that for the 1st 6 months of the year, we have an EBITDA of $41,000,000 dollars compared to a loss of $5,000,000 for the same time last year. This actually this gives us an improvement of close to $50,000,000 just comparing the 1st 6 months in the 2 years now.
And of course, I think it's not the explanation behind it. It's quite obvious. And I think we have seen strong growth in our underlying business. We have upsides relating to the corona pandemic, and we have good control on our expenses as well. And as you can see on the table on the left hand side, you can also see that we have good margin improvement in the business here.
And if you're looking at Q2, we have an EBITDA margin of 61%. And in Q1, we had an EBITDA margin of 14%. And this gives us an EBITDA margin of close to 50% for the 1st 6 months of the year, which is really good. And if this will continue going forward, yes, that remains to be seen there. So and of course, I think going into the cash flow side of the business, cash flow is, of course, dictated by the underlying growth in the business here.
And our cash position has been significantly strengthened over the last year. We had a cash balance at the end of the year at $56,000,000 which is an increase of more than $20,000,000 compared to Q1 this year and an increase of $35,000,000 compared to the same time last year. And with that, I think I can say from a financial perspective, Q2 has been an exceptional quarter that gives us a solid foundation for future growth and profitability. And with that, I think I will hand it over to you, Jethro, to tell us a little bit more on what we can expect going forward now.
Thank you, Birger, and really getting me under the hood on what's driving the business with the numbers. So thank you. So we're going through the outlook now, and it's really what to expect for the rest of the year and beyond. And a key focus for us is really about driving the strategic growth and profitability. When it comes to profitability, we fully expect to deliver on our number one goal in achieving profitability during 2020.
It just really speaks for itself when you look at the numbers there. When it comes to the coronavirus sides, we've seen the peak of the outbreak in Q2. Now we're at the back end of that outbreak. Also, we have seen in the supply chain that customers have very well stocked up. What we've seen is in many ways customers have been it's a bit like the toilet roll syndrome, where all toilet rolls are scarce.
So people are just buying them up. And we've seen that somewhat here in the market here, where assay developers are buying a lot of enzymes in excess. So with that, with those factors in play, we do expect that the upsides we've had in corona will be lower during the second half. But of course, when it comes to corona, as mentioned, our focus is, yes, the upsides are very nice. These things were never planned for the business.
But what we are focusing on here is more the longer term where we want to get our enzymes locked into the next generation tests. That's where the long term value is created. The 3rd component here is really about focusing on growth, and it is really about we've seen we have very nice growth in the underlying business. This is the business when you strip away corona. That's that long term business that we've been growing year on year.
And of course, with our underlying business, it's based on new customers that's coming on board, long term that become long term customers of ours. And they start buying products, one product, then they buy other enzymes and those relationships grow. So that business is growing. The momentum is continuing to grow there. And of course, going into the second half, we expect that growth to continue in the underlying business.
And again, the corona is just the cherry on top, no upside on top of that. But of course, growth is also about and to the satellite growth is really about what you do in the future and bringing in new opportunities. So we have our existing business and we're going to continue that will grow and we want to continue growing those existing relationships by putting new by getting them to take on more products. But also it's about finding new customers as well. So a lot of the focus is towards new opportunities where we want to drive so here, we want to cement the foundations for 2021 and beyond.
And that's what the team is really working on. And also, this relates to the new innovations we're doing. New enzymes we're bringing on market, also opens up new opportunities for us in the market. So that's a little bit of a flavor where we're going into the second half. And with that, I'd like to end there.
And we can unmute microphones and answer any questions you have. So thank you.
Jeff, can you hear me?
Yes.
This is David Seftolone of Indian Partners.
Hi, David.
What a fantastic quarter. Congratulations. Really beat our wildest expectations, I must say. But I guess, setting corona aside, as you always already you always want to point out that this is a short term upside, obviously. And the reason that we're really excited about Artexam to start with is the gene therapy exposure that you have.
I was just listening to a presentation by the Sarepta Therapeutics CEO the other day pointing out that there are 800 INDs at the FDA for different gene therapies, and there are some 300 projects undergoing clinical research at the moment. Can you talk about the potential for Arctic Symes in the gene therapy field? Long term, how many of these 300 therapies in clinic are viral based? And also, do you have any insight to such number for the INDs at the FDA? And if you can talk about volume ramp up for you when such a project typically moves from preclinical to Phase I to Phase II and then into, yes, production, I guess?
Yes. I can talk to some of that. There's a lot there. So I can give you a kind of perspective where we are. So let's start from products.
2 areas we're focusing on is we're very much focused on AAV and that's been the main virus that's been used in gene therapy and that's where our SANHQ enzyme has been focused and that's where most of the sales are today in that area. What we did is, but we know in gene therapy, there are other viruses used, such as lentivirus and that's actually used in cell therapy for CAR T, things like that as well. So we want to push down that area as well, and that's why we launched another SAN enzyme, MSAN, we launched not so long ago, and that's for targeting that market for that type of virus and other viruses too. So we want to capture as much we want to have enzymes here that will be able to touch all viruses here so we can capture anybody making virus at the end of the day. Of course, when it comes to gene therapy, you're right.
Virus is one way to gene therapy using viruses. There are other ways of delivering. And for everybody on the call here, let's make it simple. Why do you use virus? Well, virus is basically like a microscopic syringe.
It will inject a therapeutic DNA into cells. That's why you use virus. There are other delivery mechanisms out there, which can be, for instance, lipid based, where you have fats that delivers the therapeutic DNA into cells. There's also technology like CRISPR, gene editing technology that is being considered, but that's in a much earlier stage. But there, that technology can also be used viruses as well.
And then of course, when you take the cells out of patients and modify them and put them in, that's a kind of gene therapy itself therapy. There, you can use electrogression or use electric shock to get DNA into cells. So of course, shock to get DNA into cells. So of course, you have all these technologies out there when it comes to modifying DNA. And but at the end of the day, it really depends on the individual disease and the therapeutic regime you need to which one of these tools you select.
So I think when you look at, well, how much of this is related to viral diagnostics. At least somewhere we are, what we've had in terms of our customer base and opportunities in the pipeline and our funnel, we're working with over 100 customers when it comes to people developing viral diagnostics. And we know not everybody is going to be successful there. But the point is here, we have such a broad portfolio of customers that we know some of those will drop off, of course, as you do in any therapeutic area. So but what's important to stress is none of the customers we have today are commercialized yet.
They are all preclinical or early clinical trial stage. And what I alluded to earlier is that in terms of scale and what we've seen is when customers start out, they buy a few thousand kroner of product to start with, but then that rapidly ramps. So and if you think of some of our earlier customers we started working with back in 2016, Today, they're putting individual orders in of over NOK 1,000,000 and that is just for and remember, they haven't commercialized at this stage and we do expect larger orders from those customers down the road. So I think I'm trying to give you a flavor of the business on how it materializes. We are still at the early stage in terms of our relationships with our customers here.
So I hope that David, does that give you a bit more perspective of where we are? Yes. It's a very interesting question. It could take a very long time to answer in a lot more detail.
But what a blockbuster gene therapy, for example, what would such drug require in terms of enzyme volumes?
Yes. You're looking at there's 2 things here. 1 is today we're not there. I think when you look at somebody going into therapeutic, let's say somebody reaches that and nobody has yet. So this is still theoretical for us.
You'd probably be looking between NOK 5,000,000 to NOK 10,000,000 and that's putting my neck up because we're not actually locked down with nobody's at that stage yet. That's the kind of what we're looking at as a kind of annual sale. But again, it depends what the therapeutic regime is and because, of course, each disease you're targeting is different, will require a different type of virus
and different things need to be taken into account
here. But that's the kind of volumes that we see. And I think what we've seen in the industry and this is something which is very well published out there, it is difficult to achieve the scale that is needed for the therapeutic demand in the future. So this is why companies are very much looking at that scale up to get the scalability they need for the treatments down the line. So and of course, and this is why we're already prepared for the we're preparing with scaling up the sand products.
So we have that commercial scale needed as our customers move towards commercialization. But again, when I said about commercialization, of course, a lot of enzymes you use during development, but we know not everybody is going to be successful. Some of those clinical trials will fail. That's natural. But since there are a vast opportunity funnel with different customers we're working with, I think that's the beauty of it.
We if some fall off, it doesn't matter. We have enough customers in our pipeline to handle that. But I think the numbers show for itself how this business is progressing for us. And of course, we're looking at how can we capture more value there in our innovations as well. There are other things we can do to take more value here.
Any other questions? Hello. Hello. It's Mikkelsen here. I have a question about Cod Ang.
So there's a huge volume of PCR tests globally for COVID, including Thermo Fisher and many others. So how successful can you be in penetrating this market with Kodong going forward? And will you actively do something to achieve greater penetration?
Exactly. And that's part of let's come back to what we talked about with the innovations. One of the grants that we have and something that we want to do is don't get me wrong, the upsides are nice and we want that's good, we're able to do it. But what we want to do is take advantage of the longer term potential of coronavirus and viral diagnostics. Corona is just one virus.
There's a lot of other viruses out there. Of course, we want to make sure that we make enzymes that are optimized for viral diagnostics. And Code UNG is one of those. So the grant we have got and irrespective we've got the grant or not, we would have done it anyway, but it just gives us some extra fuel. What we're going to do is we're going to develop other content around COD UNG where we optimize other enzymes Because when you do a viral diagnostic COVID-nineteen test, it's not just one enzyme you're using quite a few several different enzymes to make that test.
And what we want to do is to provide all those enzymes that are also optimized to work together. And in that kind of environment, you need when you do the to be tailored for viruses. So that's part of what we're doing. We actually want to do that. We want to take more of the value chain and just not make it about CODU NG.
We're going to make those polymerases, the hot polymerases, which are used in PCR. We also want to make the reverse transcriptases. These are the enzymes that converts a different genetic molecule, RNA to DNA. And of course, we want to optimize some of our other enzymes, such as our isothermal polymerases, and those enzymes are used in non PCR amplification technologies like LAMP. But we want to optimize it to fit for optimized survival diagnostics.
So it's already on our innovation map. We're working on it. We want to capture more value from that beyond just the COD UMG. And when you look at COD UMG, this is very much we've seen many new customers come on board, our existing customers in Q2, integrating CoguNG into their rapidly launched COVID-nineteen tests. So and then we're being very well positioned operationally to take advantage of all those upsides that are coming.
We've had that flexibility in production to accommodate those upsides. But of course, we want to capture more of your other enzymes down the line.
Thank you. Anyone else? Unless there are any further questions, I think we just thank you all for participating at this second quarter presentation. And I think we just leave it at that.
Thank you. Thank you, everyone.
Have a
good day. Have a
good day. Thank you.